New combination improves outcomes for small cell bladder and neuroendocrine prostate cancer patients: early stage but clinical study
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 2: Food as Medicine Research from City Of Hope
/in Clinical Trial, Non-Metastatic, Phase 2/by MaxAnother Potential Breakthrough: 3-in-1 Antibody Shows Promise
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxApalutamide Shows Promising Survival Outcomes in Metastatic Castration-Sensitive Prostate Cancer: A Real-World Analysis
/in Observational, Post-hoc, Retrospective studies/by MaxAn add-on strategy to maximize workouts: electro stimulation works for cancer patients
/in Clinical Trial, Metastatic/by MaxHopefully a Breakthrough: CLSP-1025 Targets Common p53 Mutation, Paving New Path for Solid Tumor Immunotherapy
/in Immunotherapy, Not PCa related, Preclinical Research/by MaxUnlocking the Fortress: Good News for Immunotherapy Directed to Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxAnother AlphaFold evolution: Using AI to Identify Better Antibody Therapies
/in Artificial Intelligence, Not PCa related/by MaxAlphaFold keeps rocking: a new AI tool that can predict large proteins
/in Artificial Intelligence/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone abiraterone acetate ADC ADT AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Two-Pronged Drug Combination for Advanced Prostate Cancer: Fadraciclib Plus Ipatasertib (or Capivasertib) October 16, 2025
- Phase 2: Copper-Based PET Imaging Agent Surpasses Standard Tracer for Early Prostate Cancer Lesion Detection October 16, 2025
- Phase 2 Trial: Optimal PSA-Triggered Intermittent Therapy for mHSPC October 15, 2025
- Self-Assembled Nano-PROTAC to Improve Targeted Therapy in Castration-Resistant Prostate Cancer October 15, 2025